1. Home
  2. SHPH vs REVB Comparison

SHPH vs REVB Comparison

Compare SHPH & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHPH
  • REVB
  • Stock Information
  • Founded
  • SHPH 2012
  • REVB 2020
  • Country
  • SHPH United States
  • REVB United States
  • Employees
  • SHPH N/A
  • REVB N/A
  • Industry
  • SHPH Biotechnology: Pharmaceutical Preparations
  • REVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHPH Health Care
  • REVB Health Care
  • Exchange
  • SHPH Nasdaq
  • REVB Nasdaq
  • Market Cap
  • SHPH 2.3M
  • REVB 2.6M
  • IPO Year
  • SHPH 2022
  • REVB N/A
  • Fundamental
  • Price
  • SHPH $0.17
  • REVB $0.85
  • Analyst Decision
  • SHPH
  • REVB
  • Analyst Count
  • SHPH 0
  • REVB 0
  • Target Price
  • SHPH N/A
  • REVB N/A
  • AVG Volume (30 Days)
  • SHPH 12.3M
  • REVB 217.6K
  • Earning Date
  • SHPH 05-08-2025
  • REVB 05-08-2025
  • Dividend Yield
  • SHPH N/A
  • REVB N/A
  • EPS Growth
  • SHPH N/A
  • REVB N/A
  • EPS
  • SHPH N/A
  • REVB N/A
  • Revenue
  • SHPH N/A
  • REVB N/A
  • Revenue This Year
  • SHPH N/A
  • REVB N/A
  • Revenue Next Year
  • SHPH N/A
  • REVB N/A
  • P/E Ratio
  • SHPH N/A
  • REVB N/A
  • Revenue Growth
  • SHPH N/A
  • REVB N/A
  • 52 Week Low
  • SHPH $0.16
  • REVB $0.83
  • 52 Week High
  • SHPH $4.71
  • REVB $60.80
  • Technical
  • Relative Strength Index (RSI)
  • SHPH 30.47
  • REVB 16.76
  • Support Level
  • SHPH $0.16
  • REVB $0.83
  • Resistance Level
  • SHPH $0.18
  • REVB $2.68
  • Average True Range (ATR)
  • SHPH 0.02
  • REVB 0.26
  • MACD
  • SHPH 0.00
  • REVB -0.22
  • Stochastic Oscillator
  • SHPH 10.19
  • REVB 0.80

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: